JERUSALEM, Nov. 12, 2019 /PRNewswire/ -- Intec Pharma Ltd.
(NASDAQ: NTEC) ("Intec" or "the Company") today announces financial
results for the three and nine months ended September 30, 2019.
Highlights of the third quarter 2019 and recent weeks
include:
- Presented two posters highlighting data from the Company's
Phase 3 clinical development program for the Accordion
Pill® Carbidopa/Levodopa (AP-CD/LD) at
the International Congress of Parkinson's and Movement
Disorder Society (MDS 2019);
- Completed the qualification studies for the commercial scale
manufacture of AP-CD/LD with our partner, LTS
LohmanTherapie-Systeme (LTS);
- Announced topline results from the Company's pivotal Phase 3
trial (ACCORDANCE) evaluating the safety and efficacy of the
AP-CD/LD compared with immediate release CD/LD (IR-CD/LD;
Sinemet®) as a treatment for the symptoms of advanced
Parkinson's disease (PD), reporting that AP-CD/LD provided
treatment for Parkinson's disease symptoms but did not demonstrate
statistical superiority to IR-CD/LD in terms of reduction in OFF
time from baseline under the conditions established in the
protocol; and
- Completed the pharmacokinetic (PK) study of the custom-designed
AP developed for a proprietary compound under the previously
announced feasibility and option agreement with Novartis
Pharmaceuticals.
Management Commentary
"We gained important information and knowledge from the
ACCORDANCE study that we believe makes AP-CD/LD an attractive
partnership opportunity for late-stage development and
commercialization. First, the ACCORDANCE results validate the AP
platform and provide very important long-term safety data. The
responder analysis and subset analyses provide key insights for
future study design and dosing that should be invaluable to a
potential partner. We have qualified the commercial scale
manufacturing process with LTS, which can also be used to provide
clinical supply for the next Phase 3 study. This is a key advantage
as Chemistry, Manufacturing and Controls (CMC) is a critical
component in drug development and one that often trips up small
companies. Importantly, there continues to be a large unmet need
for a better baseline LD, which we believe provides a significant
market opportunity of between $200 -
$500 million," stated Jeffrey A. Meckler, Vice Chairman and Chief
Executive Officer of Intec Pharma.
"We were delighted to present two posters highlighting AP-CD/LD
at MDS 2019 in late September. We were particularly pleased to have
our Phase 3 ACCORDANCE clinical trial poster chosen for the
conference's Guided Tour, a distinction that drives attendees to
view the approximately ten percent of posters selected for
inclusion. Consequently, there was considerable interest in our
program's results. We believe the data underscored the potential of
AP-CD/LD as a better baseline levodopa therapy in PD while
highlighting its long-term safety data. In tandem, we are in the
process of seeking to partner AP-CD/LD in PD and found it most
beneficial to have these data delivered at this important medical
meeting. The continued understanding of the full dataset from
ACCORDANCE will be important as we seek to partner AP-CD/LD for
late-stage clinical development and commercialization in PD
patients.
"Moving forward, we continue to glean important learnings from
the ongoing data analysis. As we present these to potential
partners, we continue to advance the buildout of our commercial
manufacturing process with LTS. As noted, having these state-of-the
art commercial scale production facilities in place is expected to
be of great value to any potential partner. We will also be
completing the required regulatory submissions and reports that are
necessary for clinical and CMC filings, which we expect to further
enhance partnership opportunities.
"In July 2019, Intec provided
Novartis with the results from a human PK study of a
custom-designed AP for one of Novartis' proprietary compounds. The
study demonstrated that the AP met the technical requirements set
forth by Novartis. Novartis undertook a full commercial assessment
of the program, and to date, has not definitively decided whether
they will opt into negotiations for a commercial agreement. As a
result, we have determined that we will not need the volume of
clinical manufacturing to support that program at this time and
plan to restructure those dedicated to the Novartis program in
order to reduce our burn.
"We continued to invest in building out the Company's next phase
of growth through the AP platform's innovation engine as it can
provide multiple opportunities for pipeline expansion. Toward
that end, we were delighted to partner with Merck & Co. on a
research collaboration to develop a custom-designed AP for one of
Merck's proprietary compounds in May
2019. Our team is hard at work constructing the films for
this research collaboration and we aim to have a final construct
completed and in-vitro tested by the middle of next
year.
"The development of our AP containing synthetic
tetrahydrocannabinol (THC), one of the primary cannabinoids
contained in cannabis, completed an initial PK study earlier this
year. The results showed that the delivery of THC did not meet our
full expectations for this program. Our R&D team is in the
process of refining the AP-THC in order to fully meet our
specifications for the oral delivery of THC and CBD. We are
seeking to launch a PK study with the optimized AP-THC next
year.
"In addition to our current development pipeline, our team
continues to advance discussions with other potential
pharmaceutical partners for the development of new custom-designed
APs. We believe the data from our ACCORDANCE trial enhances those
discussions as it validates the AP platform and provides long-term
safety data. Our goal remains to add one or two new programs per
year. We believe this is the most efficient strategy for building
our pipeline and for creating value from our platform.
"Our mission remains steadfast; to build value by leveraging
the potential of our AP platform to enhance the
characteristics of a number of proprietary compounds and to develop
innovative approaches to the treatment of diseases. Our growth
strategy continues to focus on advancing a mix of internally-led
programs with partnered programs believing that having a variety of
'shots on goal' will provide Intec with a growing
pipeline and long-term royalty stream with the potential to create
significant value over time," concluded Mr. Meckler.
Financial Highlights for the Three and Nine Months Ended
September 30, 2019
Research and development expenses, net, for the three-month
period ended September 30, 2019 were
approximately $8.4 million, an
increase of approximately $600,000 or
8%, compared with approximately $7.8
million for the third quarter of 2018. The increase for the
three-month period was primarily due to an increase in expenses
related to the open label extension study. This increase was offset
by a decrease in expenses related to the ACCORDANCE study and a
decrease in expenses related to the scale up activities for the
commercial scale production capabilities for AP-CD/LD at LTS.
Research and development expenses, net, for the nine-month period
ended September 30,
2019 amounted to approximately $24.9
million, a decrease of approximately $200,000, or 1%, compared with approximately
$25.1 million in the nine-month
period ended September 30, 2018. The
decrease for the nine-month period was primarily due to a decrease
in expenses related to the ACCORDANCE study. This decrease was
offset by an increase in expenses related to the scale up
activities for the commercial scale production capabilities for
AP-CD/LD at LTS and expenses related to our open label extension
study.
General and administrative expenses for the three-month period
ended September 30, 2019 were
approximately $2.2 million, an
increase of approximately $500,000 or 29%, compared with approximately
$1.7 million in third quarter of
2018. General and administrative expenses for the nine-month period
ended September 30, 2019 amounted to
approximately $6.5 million, an increase of
approximately $700,000, or 12%, compared with
approximately $5.8 million in the nine-month period
ended September 30, 2018. The increase for the three and
nine-month periods was primarily related to the increase in payroll
and related expenses mainly due to salary raises and increase in
insurance expenses, offset by a decrease in professional
services.
Impairment of long-lived assets was recorded as the top-line
results of the ACCORDANCE trial were considered a triggering event
for impairment. For the three and nine months ended September 30, 2019, we recorded an impairment
charge of approximately $9.8 million.
This impairment represents the excess carrying value of the
long-lived assets compared to its fair value.
Net loss for the three-month period ended September 30, 2019 was approximately $20.4 million, compared with a net loss of
$9.2 million in the prior year's
third quarter. Net loss for the nine-month period ended
September 30, 2019 was $41.0 million compared with $30.9 million during the nine-month period ended
September 30, 2018.
Loss per ordinary share for the three-month period ended
September 30, 2019 was $0.61 compared with a loss per ordinary share of
$0.28 for the three-month period
ended September 30, 2018. Loss per
ordinary share for the nine-month period ended September 30, 2019 was $1.23 compared with a loss per ordinary share of
$1.01 for the nine-month period ended
September 30, 2018.
As of September 30, 2019, the
Company had cash and cash equivalents and marketable securities of
approximately $15.7 million compared
with approximately $40.6 million at
December 31, 2018.
Net cash used in operating activities during the nine-month
period ended September 30, 2019 was
approximately $23.9 million compared
with net cash used in operating activities of approximately
$30.9 million during the
nine-month period ended September 30,
2018. This decrease resulted from changes in operating
assets and liabilities items of approximately $6.5 million and a decrease in the net loss for
the period in the amount of $500,000.
The Company had negative cash flow from investing activities of
approximately $2.5 million during the
nine-month period ended September 30,
2019 compared to negative cash flow from investing
activities of approximately $5.1
million during the nine-month period ended September 30, 2018. This decrease resulted
primarily from a decrease in purchase of property and equipment in
the amount of approximately $1.8
million, an increase in proceeds from the disposal of
marketable securities in the amount of approximately $576,000 and a decrease of approximately
$135,000 in investment in other
assets related to the establishment of the commercial scale
production capabilities for AP-CD/LD at LTS.
Net cash provided by financing activities during the nine-month
period ended September 30, 2019 was
approximately $2.2 million, which was
provided by approximately $2.0
million in funds received from the sale of 1,716,679
ordinary shares under the Company's "at-the-market" equity offering
program and $268,000 in proceeds from
the exercise of options by employees.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes two product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is in late-stage development for the treatment of
Parkinson's disease symptoms in advanced Parkinson's disease
patients, and AP-cannabinoids, an Accordion Pill to deliver either
or both of the primary cannabinoids contained in Cannabis sativa,
cannabidiol (CBD) and tetrahydrocannabinol (THC) for various pain
indications. In addition, the Company has a feasibility agreement
for the development of a custom-designed Accordion Pill for a
proprietary compound with Novartis Pharmaceuticals and a research
collaboration with Merck & Co.
For more information, visit www.intecpharma.com. Intec Pharma
routinely posts information that may be important to investors in
the Investor Relations section of its website.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward looking statements about our
expectations, beliefs and intentions. Forward-looking statements
can be identified by the use of forward-looking words such as
"believe", "expect", "intend", "plan", "may", "should", "could",
"might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and we undertake no duty to update or revise any
such statements, whether as a result of new information, future
events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties,
many of which are outside of our control. Many factors could cause
our actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements,
including, but not limited to, the following: our limited operating
history and history of operating losses, our ability to continue as
a going concern, our ability to obtain additional financing, our
ability to successfully operate our business or execute our
business plan, our ability to enter into collaborative, licensing,
and other commercial relationships and on terms commercially
reasonable to us, the timing and cost of our clinical trials, the
completion and receiving favorable results in our clinical trials,
our ability to obtain and maintain regulatory approval of our
product candidates, our ability to protect and maintain our
intellectual property and licensing arrangements, our ability to
develop, manufacture and commercialize our product candidates, the
risk of product liability claims, the availability of
reimbursement, and the influence of extensive and costly government
regulation and our ability to remain listed on the Nasdaq Capital
Market. More detailed information about the risks and uncertainties
affecting us is contained under the heading "Risk Factors" included
in our most recent Annual Report on Form 10-K filed with the SEC on
February 27, 2019, and in other
filings that we have made and may make with the Securities and
Exchange Commission in the future.
-Tables to Follow-
INTEC PHARMA
LTD.
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
(Unaudited)
|
|
|
|
|
|
September 30, 2019
|
|
December 31, 2018
|
|
U.S. dollars in thousands
|
Assets
|
|
|
|
CURRENT
ASSETS:
|
|
|
|
Cash and cash
equivalents
|
$
14,966
|
|
$
39,246
|
Investment in
marketable securities
|
767
|
|
1,333
|
Prepaid expenses and
other receivables
|
2,453
|
|
2,986
|
TOTAL CURRENT
ASSETS
|
18,186
|
|
43,565
|
|
|
|
|
NON-CURRENT
ASSETS:
|
|
|
|
Other
assets
|
4,204
|
|
5,431
|
Property and
equipment, net
|
6,200
|
|
12,233
|
Operating lease
right-of-use assets
|
1,687
|
|
-
|
Deferred tax
assets
|
504
|
|
281
|
TOTAL NON-CURRENT
ASSETS
|
12,595
|
|
17,945
|
|
|
|
|
TOTAL
ASSETS
|
$
30,781
|
|
$
61,510
|
|
|
|
|
Liabilities and
shareholders' equity
|
|
|
|
CURRENT
LIABILITIES -
|
|
|
|
Accounts payable and
accruals:
|
|
|
|
Trade
|
$
4,834
|
|
$
2,849
|
Other
|
6,774
|
|
4,807
|
TOTAL CURRENT
LIABILITIES
|
11,608
|
|
7,656
|
LONG-TERM
LIABILITIES -
|
|
|
|
Non-current operating lease liabilities
|
1,132
|
|
-
|
Other liabilities
|
554
|
|
309
|
TOTAL LONG-TERM
LIABILITIES
|
1,686
|
|
309
|
TOTAL
LIABILITIES
|
13,294
|
|
7,965
|
|
|
|
|
COMMITMENTS AND
CONTINGENT LIABILITIES
|
|
|
|
SHAREHOLDERS'
EQUITY:
|
|
|
|
Ordinary
shares, with no par value - authorized: 100,000,000 Ordinary Shares
as of
September 30, 2019 and December 31, 2018; issued and outstanding:
35,019,479
and 33,232,988 Ordinary Shares as of September 30, 2019 and
December 31, 2018, respectively
|
727
|
|
727
|
Additional paid-in
capital
|
199,627
|
|
194,642
|
Accumulated
deficit
|
(182,867)
|
|
(141,824)
|
TOTAL
SHAREHOLDERS' EQUITY
|
17,487
|
|
53,545
|
TOTAL LIABILITIES
AND SHAREHOLDERS' EQUITY
|
$
30,781
|
|
$
1,510
|
INTEC PHARMA
LTD.
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
(Unaudited)
|
|
|
|
|
|
Three months
ended
September 30
|
|
Nine months
ended
September 30
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
|
U.S.
dollars
in
thousands
|
|
U.S.
dollars
in
thousands
|
OPERATING
EXPENSES:
|
|
|
|
|
|
|
|
RESEARCH AND
DEVELOPMENT EXPENSES, net
|
(8,448)
|
|
(7,809)
|
|
(24,850)
|
|
(25,089)
|
GENERAL AND
ADMINISTRATIVE EXPENSES
|
(2,157)
|
|
(1,696)
|
|
(6,491)
|
|
(5,800)
|
IMPAIRMENT OF
LONG-LIVED ASSETS
|
(9,759)
|
|
|
|
(9,759)
|
|
|
OPERATING
LOSS
|
(20,364)
|
|
(9,505)
|
|
(41,100)
|
|
(30,889)
|
FINANCIAL INCOME
(EXPENSES), net
|
14
|
|
163
|
|
157
|
|
(5)
|
LOSS BEFORE
INCOME TAX
|
(20,350)
|
|
(9,342)
|
|
(40,943)
|
|
(30,894)
|
TAX BENEFIT
(INCOME TAX)
|
(28)
|
|
164
|
|
(100)
|
|
(46)
|
NET
LOSS
|
(20,378)
|
|
(9,178)
|
|
(41,043)
|
|
(30,940)
|
|
U.S.
dollars
|
LOSS PER SHARE
BASIC AND DILUTED
|
(0.61)
|
|
(0.28)
|
|
(1.23)
|
|
(1.01)
|
WEIGHTED AVERAGE
NUMBER OF SHARES OUTSTANDING USED IN
COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE IN
THOUSANDS
|
33,516
|
|
33,226
|
|
33,356
|
|
30,505
|
(Continued) -
1
|
INTEC PHARMA
LTD.
|
CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary
Shares
|
|
Additional
paid-in
capital
|
|
Accumulated
Deficit
|
|
Total
|
|
Number of
shares
|
|
Amounts
|
|
Amounts
|
|
U.S. dollars in
thousands
|
|
|
|
|
|
|
|
|
|
|
BALANCE AT JANUARY
1, 2018
|
|
|
|
|
|
|
|
|
|
CHANGES IN THE
NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2018:
|
26,075,770
|
|
$
727
|
|
$
156,356
|
|
$
(98,281)
|
|
$
58,802
|
Issuance of ordinary
shares, net of issuance costs
|
7,150,000
|
|
-
|
|
35,029
|
|
-
|
|
35,029
|
Exercise of
options
|
218
|
|
-
|
|
1
|
|
-
|
|
1
|
Share-based
compensation
|
-
|
|
-
|
|
2,452
|
|
-
|
|
2,452
|
Net loss
|
-
|
|
-
|
|
-
|
|
(30,940)
|
|
(30,940)
|
BALANCE AT
SEPTEMBER 30, 2018
|
33,225,988
|
|
$
727
|
|
$
193,838
|
|
$
(129,221)
|
|
$
65,344
|
|
|
|
|
|
|
|
|
|
|
BALANCE AT JANUARY
1, 2019
|
|
|
|
|
|
|
|
|
|
CHANGES IN THE
NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2019:
|
33,232,988
|
|
$
727
|
|
$
194,642
|
|
$
(141,824)
|
|
$
53,545
|
Issuance of ordinary
shares, net of issuance costs
|
1,716,679
|
|
-
|
|
1,969
|
|
-
|
|
1,969
|
Exercise of
options
|
69,812
|
|
-
|
|
268
|
|
-
|
|
268
|
Share-based
compensation
|
-
|
|
-
|
|
2,748
|
|
-
|
|
2,748
|
Net loss
|
-
|
|
-
|
|
-
|
|
(41,043)
|
|
(41,043)
|
BALANCE AT
SEPTEMBER 30, 2019
|
35,019,479
|
|
$
727
|
|
$
199,627
|
|
$
(182,867)
|
|
$
17,487
|
(Continued) -
2
|
INTEC PHARMA
LTD.
|
CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary
Shares
|
|
Additional
paid-in
capital
|
|
Accumulated
Deficit
|
|
Total
|
|
|
|
Number of
shares
|
|
Amounts
|
|
Amounts
|
|
|
|
U.S. dollars in
thousands
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE AT JULY 1,
2018
|
33,225,988
|
|
$
727
|
|
$
192,987
|
|
$
(120,043)
|
|
$
73,671
|
|
|
CHANGES IN THE
THREE-MONTH PERIOD ENDED SEPTEMBER 30,
2018:
|
|
|
|
|
|
|
|
|
|
|
|
Share-based
compensation
|
-
|
|
-
|
|
851
|
|
-
|
|
851
|
|
|
Net
loss
|
-
|
|
-
|
|
-
|
|
(9,178)
|
|
(9,178)
|
|
|
BALANCE AT
SEPTEMBER 30, 2018
|
33,225,988
|
|
$
727
|
|
$
193,838
|
|
$
(129,221)
|
|
$
65,344
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE AT JULY 1,
2019
|
33,302,800
|
|
$
727
|
|
$
196,871
|
|
$
(162,489)
|
|
$
35,109
|
|
|
CHANGES IN THE
THREE-MONTH PERIOD ENDED SEPTEMBER 30,
2019:
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of ordinary
shares, net of issuance costs
|
1,716,679
|
|
-
|
|
1,969
|
|
-
|
|
1,969
|
|
|
Share-based
compensation
|
-
|
|
-
|
|
787
|
|
-
|
|
787
|
|
|
Net
loss
|
-
|
|
-
|
|
-
|
|
(20,378)
|
|
(20,378)
|
|
|
BALANCE AT
SEPTEMBER 30, 2019
|
35,019,479
|
|
$
727
|
|
$
199,627
|
|
$
(182,867)
|
|
$
17,487
|
|
|
INTEC PHARMA
LTD.
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
Nine months ended
September 30
|
|
2019
|
|
2018
|
|
U.S. dollars in
thousands
|
CASH FLOWS FROM
OPERATING ACTIVITIES:
|
|
|
|
Net loss
|
(41,043)
|
|
(30,940)
|
Adjustments
required to reconcile net loss to net cash used in operating
activities:
|
|
|
|
Depreciation
|
643
|
|
639
|
Impairment of
long-lived asset
|
9,759
|
|
|
Exchange differences
on cash and cash equivalents
|
69
|
|
(528)
|
Right of use
asset
|
523
|
|
-
|
Lease
liability
|
(380)
|
|
-
|
Losses (gains) on
marketable securities
|
(10)
|
|
141
|
Share-based
compensation
|
2,748
|
|
2,452
|
Changes in operating
assets and liabilities:
|
|
|
|
Decrease in prepaid
expenses and other receivables
|
483
|
|
(979)
|
Increase in deferred
tax assets
|
(223)
|
|
-
|
Increase in accounts
payable and accruals
|
3,268
|
|
(1,734)
|
Increase in other
liabilities
|
245
|
|
-
|
Net cash used in
operating activities
|
(23,918)
|
|
(30,949)
|
CASH FLOWS FROM
INVESTING ACTIVITIES:
|
|
|
|
Purchase of property
and equipment
|
(791)
|
|
(2,632)
|
Investment in other
assets
|
(2,315)
|
|
(2,450)
|
Proceeds from disposal
(purchase) of marketable securities, net
|
576
|
|
(38)
|
Net cash used in
investing activities
|
(2,530)
|
|
(5,120)
|
CASH FLOWS FROM
FINANCING ACTIVITIES:
|
|
|
|
Proceeds from issuance
of ordinary shares, net of issuance costs
|
1,969
|
|
35,029
|
Proceeds from exercise
of options
|
268
|
|
1
|
Net cash provided by
financing activities
|
2,237
|
|
35,030
|
DECREASE IN CASH
AND CASH EQUIVALENTS
|
(24,211)
|
|
(1,039)
|
CASH AND CASH
EQUIVALENTS AT BEGINNING OF THE PERIOD
|
39,246
|
|
53,393
|
EXCHANGE
DIFFERENCES ON CASH AND CASH EQUIVALENTS
|
(69)
|
|
528
|
CASH AND CASH
EQUIVALENTS AT END OF THE PERIOD
|
14,966
|
|
52,882
|
|
|
|
|
SUPPLEMENTAL
DISCLOSURES OF NON-CASH INVESTING ACTIVITIES:
|
|
|
|
Liability with respect
to property and equipment
|
123
|
|
1,898
|
Liability with respect
to other assets
|
549
|
|
244
|
|
|
|
|
SUPPLEMENTARY
DISCLOSURE OF CASH FLOW INFORMATION -
|
|
|
|
Taxes paid
|
50
|
|
31
|
Interest
received
|
315
|
|
522
|
Intec Pharma Investor Contact:
Anne Marie Fields
VP-Corporate Communications & Investor Relations
646-200-8808
amf@intec-us.com
View original
content:http://www.prnewswire.com/news-releases/intec-pharma-reports-third-quarter-2019-financial-results-and-provides-business-update-300956160.html
SOURCE Intec Pharma Ltd.